55837-27-9 Usage
Uses
Used in Pharmaceutical Industry:
Piretanide is used as a diuretic for the treatment of edema, which is the accumulation of excess fluid in the body's tissues. It is particularly effective in cases where the edema is caused by conditions such as heart failure, liver disease, or kidney disease. By increasing urine output, Piretanide helps to reduce the volume of fluid in the body and alleviate the symptoms of edema.
Additionally, Piretanide is used in the treatment of hypertension, or high blood pressure. As a diuretic, it helps to lower blood pressure by reducing the volume of fluid in the blood vessels, which in turn decreases the pressure exerted on the vessel walls.
Originator
Arelix ,Hoechst, Italy ,1980
Therapeutic Function
Diuretic
Safety Profile
Poison by intravenous route. Moderately toxic by ingestion, intraperitoneal, and subcutaneous routes. An experimental teratogen. Experimental reproductive effects. Used as a diuretic agent. When heated to decomposition it emits very toxic fumes of SOx an
Check Digit Verification of cas no
The CAS Registry Mumber 55837-27-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,8,3 and 7 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 55837-27:
(7*5)+(6*5)+(5*8)+(4*3)+(3*7)+(2*2)+(1*7)=149
149 % 10 = 9
So 55837-27-9 is a valid CAS Registry Number.
InChI:InChI=1/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
55837-27-9Relevant articles and documents
Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
-
, (2008/06/13)
PCT No. PCT/IB96/00254 Sec. 371 Date Nov. 20, 1997 Sec. 102(e) Date Nov. 20, 1997 PCT Filed Feb. 12, 1996 PCT Pub. No. WO96/26197 PCT Pub. Date Aug. 29, 1996Amorphous piretanide having the following characteristics a) exothermic peaks at about 136 DEG C. and about 209 DEG C., b) an endothermic peak at about 207 DEG C., and c) a melting peak at about 225 DEG C. in differential thermal curves; d) a halopattern without diffraction peak in X-ray powder diffraction analysis; and e) characteristic absorptions at around 1700 cm-1 and 3200-3500 cm-1 in infra-red absorption spectrum, and having a superior solubility around neutrality and a high bioavailability effective in the manner of oral or injection administration. Methods of preparing amorphous piretanide are also described.
Novel 4-phenoxy-5-sulfamylbenzoic acid derivatives
-
, (2008/06/13)
Novel 3-(butylamino) or (1-pyrrolidinyl)-4-phenoxy-5-sulfamylbenzoic acid derivatives where the butyl group contains either a double bond or a hydroxy, ketone, acid or ester functional group or groups, said compounds being useful as diuretics.
5-Sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent
-
, (2008/06/13)
5-Sulfamoylbenzoic acids substituted in 4-position by various substituents and in 3-position by a cyclic amino group having sali-diurectic properties, and a process for their manufacture.
